Thymalfasin, thymosin alpha 1

0

Inquiry Basket

Search

Home
Thymalfasin, thymosin alpha 1

Thymalfasin, thymosin alpha 1

Cat# : THP-0171

Product Datasheets COA :

Catalog#	Product Name	Availability	Size	Price	Qty
THP-0171	Thymalfasin, thymosin alpha 1	April 02, 2023	10mg	$598
Add to Cart Online Order Request a Bulk Order

Specification Drug Information Related Products

Cat#:	THP-0171
Product Name:	Thymalfasin, thymosin alpha 1
Description:	The product is a chemically synthesized version of thymosin alpha 1 that is identical to human thymosin alpha 1. Thymosin alpha 1 is an acetylated polypeptide.
Sequences:	SDAAVDTSSEITTKDLKEKKEVVEEAEN
Species:	Human
Molecular Weight:	3108.2755 Da
Cas No:	62304-98-7
Formula:	C129H215N33O55
Endotoxin Level:	<0.001 EU per 1 μg of the peptide by the LAL method

For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

CONTACT US

For more information on how our products could help advance your project, please contact us.

Contact Us

ENTER YOUR EMAIL HERE TO SUBSCRIBE.

Drug Name:	Thymalfasin
Applications:	Indicated as an adjuvant for influenza vaccine in elderly patients and as an adjuvant for both influenza and hepatitis B vaccines in chronic hemodialysis patients who failed to achieve adequate antibody titers from previous immunization.
Examples of Clinical Use:	Influenza and hepatitis B
Pharmacodynamics:	The product is a 28-amino acid polypeptide produced synthetically but originally isolated from thymosin fraction 5, a bovine thymus extract containing a number of immunologically active peptides. In vitro studies have shown that the product can influence T-cell production and maturation, stimulate production of Th1 cytokines such as interferon-gamma and interleukin-2, and activate natural killer cell-mediated cytotoxicity.
Mechanism of action:	The mechanism of action of thymalfasin is not completely understood but is thought to be related to its immunomodulating activities, centered primarily around augmentation of T-cell function. In various in vitro assays, thymosin alpha 1 has been shown to promote T-cell differentiation and maturation; for example, CD4+, CD8+, and CD3+ cells have all been shown to be increased. Thymosin alpha 1 has also been shown to increase production of IFN-g, IL-2, IL-3, and expression of IL-2 receptor following activation by mitogens or antigens, increase NK cell activity, increase production of migratory inhibitory factor (MIF), and increase antibody response to T-cell dependent antigens. Thymosin alpha 1 has also been shown to antagonize dexamethasone-induced apoptosis of thymocytes in vitro. In vivo administration of thymosin alpha 1 to animals immunosuppressed by chemotherapy, tumor burden, or irradiation showed that thymosin alpha 1 protects against cytotoxic damage to bone marrow, tumor progression and opportunistic infections, thereby increasing survival time and number of survivors. Many of the in vitro and in vivo effects of thymosin alpha 1 have been interpreted as influences on either differentiation of pluripotent stem cells to thymocytes or activation of thymocytes into activated T-cells. Thymalfasin also has been shown in vitro to upregulate expression of toll like receptors (TLR) including TLR2 and TLR9 in mouse and human dendritic cells, as well as activate NF-kB and JNK/P38/AP1 pathways. Thymalfasin's activation of dendritic cells provides another possible pathway explaining thymalfasin's immunomodulatory and antiviral effects.
Affected organisms:	Humans and other mammals

Thymalfasin, thymosin alpha 1

Thymalfasin, thymosin alpha 1

Online Inquiry